APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Drug based on CAR-T

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Drug based on CAR-T Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchCancer Drug based on CAR-T Industry Research Report 2026100 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Drug based on CAR-T Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Cancer Drug based on CAR-T Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Drug based on CAR-T Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Drug based on CAR-T Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Drug based on CAR-T market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Drug based on CAR-T is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Drug based on CAR-T is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Drug based on CAR-T is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Drug based on CAR-T market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Drug based on CAR-T market include Bristol-Myers Squibb, Fosun Kite Biotechnology, Gilead Sciences and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cancer Drug based on CAR-T market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Drug based on CAR-T and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Drug based on CAR-T revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cancer Drug based on CAR-T market.

Cancer Drug based on CAR-T Segment by Company

Bristol-Myers Squibb

Fosun Kite Biotechnology

Gilead Sciences

Novartis

Cancer Drug based on CAR-T Segment by Type

Allogeneic

Autologous

Cancer Drug based on CAR-T Segment by Application

Hospital

Pharmacy

Other

Cancer Drug based on CAR-T Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Cancer Drug based on CAR-T status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cancer Drug based on CAR-T key companies, revenue, market share, and recent developments.

3. To split the Cancer Drug based on CAR-T breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cancer Drug based on CAR-T market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Drug based on CAR-T significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Drug based on CAR-T competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drug based on CAR-T market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Drug based on CAR-T and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drug based on CAR-T.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Drug based on CAR-T industry.

Chapter 3: Detailed analysis of Cancer Drug based on CAR-T company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cancer Drug based on CAR-T in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cancer Drug based on CAR-T in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Drug based on CAR-T Industry Trends Table 2. Cancer Drug based on CAR-T Industry Drivers Table 3. Cancer Drug based on CAR-T Industry Opportunities and Challenges Table 4. Cancer Drug based on CAR-T Industry Restraints Table 5. Global Cancer Drug based on CAR-T Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Drug based on CAR-T Revenue Share by Company (2021-2026) Table 7. Global Cancer Drug based on CAR-T Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cancer Drug based on CAR-T Key Company Manufacturing Base & Headquarters Table 9. Global Cancer Drug based on CAR-T Company, Product Type & Application Table 10. Global Cancer Drug based on CAR-T Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cancer Drug based on CAR-T by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Allogeneic Table 15. Significant Companies of Autologous Table 16. Global Cancer Drug based on CAR-T Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Cancer Drug based on CAR-T Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Cancer Drug based on CAR-T Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Cancer Drug based on CAR-T Sales Value Share by Type (2021-2026) Table 20. Global Cancer Drug based on CAR-T Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Pharmacy Table 23. Significant Companies of Other Table 24. Global Cancer Drug based on CAR-T Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cancer Drug based on CAR-T Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Cancer Drug based on CAR-T Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Cancer Drug based on CAR-T Sales Value Share by Application (2021-2026) Table 28. Global Cancer Drug based on CAR-T Sales Value Share by Application (2027-2032) Table 29. Global Cancer Drug based on CAR-T Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cancer Drug based on CAR-T Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Cancer Drug based on CAR-T Sales Value Share by Region (2021-2026) Table 32. Global Cancer Drug based on CAR-T Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Cancer Drug based on CAR-T Sales Value Share by Region (2027-2032) Table 34. Global Cancer Drug based on CAR-T Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Cancer Drug based on CAR-T Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Cancer Drug based on CAR-T Sales Value Market Share by Country (2021-2026) Table 37. Global Cancer Drug based on CAR-T Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Cancer Drug based on CAR-T Sales Value Market Share by Country (2027-2032) Table 39. Bristol-Myers Squibb Company Information Table 40. Bristol-Myers Squibb Business Overview Table 41. Bristol-Myers Squibb Cancer Drug based on CAR-T Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Bristol-Myers Squibb Cancer Drug based on CAR-T Product Portfolio Table 43. Bristol-Myers Squibb Recent Development Table 44. Fosun Kite Biotechnology Company Information Table 45. Fosun Kite Biotechnology Business Overview Table 46. Fosun Kite Biotechnology Cancer Drug based on CAR-T Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Fosun Kite Biotechnology Cancer Drug based on CAR-T Product Portfolio Table 48. Fosun Kite Biotechnology Recent Development Table 49. Gilead Sciences Company Information Table 50. Gilead Sciences Business Overview Table 51. Gilead Sciences Cancer Drug based on CAR-T Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Gilead Sciences Cancer Drug based on CAR-T Product Portfolio Table 53. Gilead Sciences Recent Development Table 54. Novartis Company Information Table 55. Novartis Business Overview Table 56. Novartis Cancer Drug based on CAR-T Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novartis Cancer Drug based on CAR-T Product Portfolio Table 58. Novartis Recent Development Table 59. Research Programs/Design for This Report Table 60. Authors List of This Report Table 61. Secondary Sources Table 62. Primary Sources List of Figures Figure 1. Cancer Drug based on CAR-T Product Image Figure 2. Global Cancer Drug based on CAR-T Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Drug based on CAR-T Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Drug based on CAR-T Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Allogeneic Image Figure 8. Autologous Image Figure 9. Global Cancer Drug based on CAR-T Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Cancer Drug based on CAR-T Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Cancer Drug based on CAR-T Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Pharmacy Image Figure 14. Other Image Figure 15. Global Cancer Drug based on CAR-T Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cancer Drug based on CAR-T Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Cancer Drug based on CAR-T Sales Value Share by Application (2021-2032) Figure 18. Global Cancer Drug based on CAR-T Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Cancer Drug based on CAR-T Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Cancer Drug based on CAR-T Sales Value (2021-2032) & (US$ Million) Figure 21. North America Cancer Drug based on CAR-T Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Cancer Drug based on CAR-T Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Cancer Drug based on CAR-T Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Cancer Drug based on CAR-T Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Cancer Drug based on CAR-T Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Cancer Drug based on CAR-T Sales Value (2021-2032) & (US$ Million) Figure 27. South America Cancer Drug based on CAR-T Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Cancer Drug based on CAR-T Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Cancer Drug based on CAR-T Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Allogeneic
  • Autologous
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Bristol-Myers Squibb
  • Fosun Kite Biotechnology
  • Gilead Sciences
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Drug based on CAR-T Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Drug based on CAR-T Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cancer Drug based on CAR-T Market Dynamics
  1. 2.1 Cancer Drug based on CAR-T Industry Trends
  2. 2.2 Cancer Drug based on CAR-T Industry Drivers
  3. 2.3 Cancer Drug based on CAR-T Industry Opportunities and Challenges
  4. 2.4 Cancer Drug based on CAR-T Industry Restraints
3 Cancer Drug based on CAR-T Market by Company
  1. 3.1 Global Cancer Drug based on CAR-T Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Drug based on CAR-T Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Drug based on CAR-T Company Ranking (2024-2026)
  4. 3.4 Global Cancer Drug based on CAR-T Company Manufacturing Base and Headquarters
  5. 3.5 Global Cancer Drug based on CAR-T Company Product Type and Application
  6. 3.6 Global Cancer Drug based on CAR-T Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cancer Drug based on CAR-T Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cancer Drug based on CAR-T Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cancer Drug based on CAR-T Market by Type
  1. 4.1 Cancer Drug based on CAR-T Type Introduction
  2. 4.1.1 Allogeneic
  3. 4.1.2 Autologous
  4. 4.2 Global Cancer Drug based on CAR-T Sales Value by Type
  5. 4.2.1 Global Cancer Drug based on CAR-T Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cancer Drug based on CAR-T Sales Value by Type (2021-2032)
  7. 4.2.3 Global Cancer Drug based on CAR-T Sales Value Share by Type (2021-2032)
5 Cancer Drug based on CAR-T Market by Application
  1. 5.1 Cancer Drug based on CAR-T Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Cancer Drug based on CAR-T Sales Value by Application
  6. 5.2.1 Global Cancer Drug based on CAR-T Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Drug based on CAR-T Sales Value by Application (2021-2032)
  8. 5.2.3 Global Cancer Drug based on CAR-T Sales Value Share by Application (2021-2032)
6 Cancer Drug based on CAR-T Regional Value Analysis
  1. 6.1 Global Cancer Drug based on CAR-T Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Drug based on CAR-T Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cancer Drug based on CAR-T Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cancer Drug based on CAR-T Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Drug based on CAR-T Sales Value (2021-2032)
  7. 6.3.2 North America Cancer Drug based on CAR-T Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cancer Drug based on CAR-T Sales Value (2021-2032)
  10. 6.4.2 Europe Cancer Drug based on CAR-T Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cancer Drug based on CAR-T Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cancer Drug based on CAR-T Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cancer Drug based on CAR-T Sales Value (2021-2032)
  16. 6.6.2 South America Cancer Drug based on CAR-T Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cancer Drug based on CAR-T Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cancer Drug based on CAR-T Sales Value Share by Country, 2025 VS 2032
7 Cancer Drug based on CAR-T Country-level Value Analysis
  1. 7.1 Global Cancer Drug based on CAR-T Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Drug based on CAR-T Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cancer Drug based on CAR-T Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cancer Drug based on CAR-T Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cancer Drug based on CAR-T Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cancer Drug based on CAR-T Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cancer Drug based on CAR-T Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Cancer Drug based on CAR-T Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Cancer Drug based on CAR-T Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Fosun Kite Biotechnology
  8. 8.2.1 Fosun Kite Biotechnology Company Information
  9. 8.2.2 Fosun Kite Biotechnology Business Overview
  10. 8.2.3 Fosun Kite Biotechnology Cancer Drug based on CAR-T Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Fosun Kite Biotechnology Cancer Drug based on CAR-T Product Portfolio
  12. 8.2.5 Fosun Kite Biotechnology Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Cancer Drug based on CAR-T Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Cancer Drug based on CAR-T Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Cancer Drug based on CAR-T Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Cancer Drug based on CAR-T Product Portfolio
  24. 8.4.5 Novartis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst